Amid Advances in Lipid-Based Delivery, Some See Other Technologies Being Passed Over | GenomeWeb

By Doug Macron

Alnylam Pharmaceuticals' release of interim phase I data last week showing that its intravenous siRNA-based liver cancer drug could trigger an RNAi effect in humans when administered using Tekmira Pharmaceuticals' lipid nanoparticle technology marked a key milestone in overcoming the delivery challenge facing RNAi therapeutics (GSN 1/6/2011).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: genetic method to gauge age of ancient samples, genetic polymorphisms in mouse strain, and more.

Two Stanford professors are turning to the online game EteRNA to develop a new way to diagnose tuberculosis.

Lita Nelsen from the Massachusetts Institute of Technology's technology-transfer office is retiring after decades there.

After nine years, the Canadian government is loosening its restrictions on government scientists' ability to speak to the press and public.